Filtered By:
Cancer: Breast Cancer
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 450 results found since Jan 2013.
Integrative landscape analysis of prognostic model biomarkers and immunogenomics of disulfidptosis-related genes in breast cancer based on LASSO and WGCNA analyses
CONCLUSION: The risk score model was effective for predicting both prognosis and sensitivity to therapeutic drugs, suggesting its possible usefulness for the management of patients with breast cancer.PMID:37736788 | DOI:10.1007/s00432-023-05372-z
Source: Clinical Breast Cancer - September 22, 2023 Category: Cancer & Oncology Authors: Shuyan Liu Yiwen Zheng Shujin Li Yaoqiang Du Xiaozhen Liu Hongchao Tang Xuli Meng Qinghui Zheng Source Type: research
Identification of a TRP channel-related risk model for predicting prognosis and therapeutic effects of patients with hepatocellular carcinoma
CONCLUSIONS: We successfully established a highly accurate prognostic model for predicting overall survival and therapeutic effects using TRP channel-related genes.PMID:37733242 | DOI:10.1007/s00432-023-05394-7
Source: Clinical Breast Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Chong Pang Zhe Xu Jilong Han Fujun Li Hongyan Zhu Jiaqi Zhang Dong Wang Xundi Xu Source Type: research
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer
CONCLUSION: A subset of patients (10%) receiving trastuzumab in the metastatic setting have achieved long-term survival beyond 20 years.PMID:37725049 | DOI:10.1093/oncolo/oyad258
Source: The Oncologist - September 19, 2023 Category: Cancer & Oncology Authors: Juan Luis Gomez Marti Azadeh Nasrazadani Ying Ding Daniel Normolle Adam M Brufsky Source Type: research
In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
Conclusions TNBC is a difficult-to-treat oncologic condition, even in an experimental setting. Promising results concerning the addition of targeted therapies (dasatinib) to the conventional cytotoxic ones (docetaxel) have been shown, awaiting further evaluation.PMID:37719631 | PMC:PMC10500968 | DOI:10.7759/cureus.43534
Source: Cancer Control - September 18, 2023 Category: Cancer & Oncology Authors: Ioannis D Passos Dimochristos Papadimitriou Areti Katsouda Georgios E Papavasileiou Apostolos Galatas Panagiotis Tzitzis Alexandra Mpakosi Maria Mironidou-Tzouveleki Source Type: research
A novel self-assembled nanoplatform based on retrofitting poloxamer 188 for triple-negative breast cancer targeting treatment
In this study, a novel self-assembled nanoplatform was developed for active targeting of folate receptor-overexpressing triple-negative breast cancer. This platform, FPP NPs, was prepared by the retrofitted poloxamer 188 derivatives, resulting in nanoparticles with an appropriate size (<100 nm), good stability, and satisfactory biocompatibility. Cellular uptake and in vivo distribution studies showed that the FPP NPs had strong tumor cell uptake and active targeting capabilities. Furthermore, docetaxel (DTX) was loaded into FPP NPs in this research. The resulting DTX/FPP NPs exhibited high drug encapsulation efficiency ...
Source: Chemico-Biological Interactions - September 16, 2023 Category: Molecular Biology Authors: Xueyan Hou Yalin Guan Sisi He Zeqing Wu Jintao Bai Jingjing Xu Jingwen Wang Suyue Xu Huiqing Zhu Yanyan Yin Xue Yang Yongli Shi Source Type: research
Efficacy and safety of a dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in women with breast cancer: a multicentre, open-label, randomised phase 2 study
CONCLUSIONS: The dexamethasone-based mouthwash safely reduced stomatitis incidence and severity in patients receiving chemotherapy for early breast cancer. Phase 3 clinical trials are warranted for validating our results.PMID:37689451 | DOI:10.1016/j.jebdp.2023.101896
Source: Cancer Control - September 9, 2023 Category: Cancer & Oncology Authors: Sayaka Kuba Shigeto Maeda Kenichiro Shibata Sakiko Soutome Kosho Yamanouchi Megumi Matsumoto Aya Tanaka Michi Morita Toshiko Hatachi Ryota Otsubo Hiroshi Yano Yumiko Kawashita Shuntaro Sato Hideki Taniguchi Kengo Kanetaka Masahiro Umeda Takeshi Nagayasu S Source Type: research
Tumor-derived exosomes RNA expression profiling identifies the prognosis, immune characteristics, and treatment in HR+/HER2-breast cancer
Aging (Albany NY). 2023 Aug 29;15. doi: 10.18632/aging.204986. Online ahead of print.ABSTRACTExosomes play crucial roles in intercellular communication and are involved in the onset and progression of various types of cancers, including breast cancer. However, the RNA composition of breast cancer-derived exosomes has not been comprehensively explored. We conducted microarray assays on exosomes isolated from breast cancer and healthy breast epithelial cells from three patients with hormone receptor (HR) +/ human epidermal growth factor receptor (HER2) - breast cancer and identified 817 differentially expressed genes (DEGs)....
Source: Aging - August 30, 2023 Category: Biomedical Science Authors: Qi Zhou Jing Wang Haiping Zhang Lu Sun Jingjing Liu Lingchao Meng Jingwu Li Source Type: research
Effect of chemotherapy and different chemotherapy regimens on bone health among Chinese breast cancer women in different menstrual status: a self-control study
CONCLUSION: Chemotherapy might induce lumbar vertebrae BMD loss and spine osteoporosis with regimen differences among Chinese BC patients. Calcium/VitD supplementation could improve bone turnover markers, bone metabolism indicators, and bone mineral density. Early interventions on bone health are needed for BC patients during chemotherapy.PMID:37642751 | DOI:10.1007/s00520-023-07960-8
Source: Cancer Control - August 29, 2023 Category: Cancer & Oncology Authors: Bai-Qing Peng Juan Wu Shen Tian Xiu-Quan Qu Xin-Yu Liang Jun-Han Feng Yu-Ling Chen Rui-Ling She Chen-Yu Ma Jing-Yu Song Zhao-Xing Li Zhi-Yu Jiang Kai-Nan Wu Ling-Quan Kong Source Type: research
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins
Cancer Res Commun. 2023 Aug 15;3(8):1551-1563. doi: 10.1158/2767-9764.CRC-22-0501. eCollection 2023 Aug.ABSTRACTTriple-negative breast cancer (TNBC) constitutes 10%-15% of all breast tumors. The current standard of care is multiagent chemotherapy, which is effective in only a subset of patients. The original objective of this study was to deploy a mass spectrometry (MS)-based kinase inhibitor pulldown assay (KIPA) to identify kinases elevated in non-pCR (pathologic complete response) cases for therapeutic targeting. Frozen optimal cutting temperature compound-embedded core needle biopsies were obtained from 43 patients wit...
Source: Cell Research - August 17, 2023 Category: Cytology Authors: Junkai Wang Alexander B Saltzman Eric J Jaehnig Jonathan T Lei Anna Malovannaya Matthew V Holt Meggie N Young Mothaffar F Rimawi Foluso O Ademuyiwa Meenakshi Anurag Beom-Jun Kim Matthew J Ellis Source Type: research
